


PRODUCT INFORMATION



Eclitasertib

Item No. 45472

CAS Registry No.: 2125450-76-0
Formal Name: 4-[2-[(cyclopropylsulfonyl)amino]-4pyrimidinyl]-N-[5-(6-ethoxy-2-pyrazinyl)-2-pyridinyl]tetrahydro-2H-pyran-4-carboxamide
Synonyms: DNL758, SAR443122
MF: C₁₉H₁₈N₆O₃
FW: 378.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Eclitasertib is supplied as a solid. A stock solution may be made by dissolving the eclitasertib in the solvent of choice, which should be purged with an inert gas. Eclitasertib is sparingly soluble (1-10 mg/ml) in DMSO.

Description

Eclitasertib is an inhibitor of receptor-interacting serine/threonine kinase 1 (RIPK1; IC₅₀ = 0.0375 μM).¹ It inhibits necroptosis induced by TNF-α, a Smac mimetic, and Z-VAD-FMK in HT-29 cells (EC₅₀ = 0.0154 μM, respectively).² Eclitasertib (4 nM) inhibits necroptosis induced by IFN-γ, TNF-α, Z-VAD, and an Smac mimetic and reduces cytokine levels induced by the same combination in primary human keratinocytes.³ It reduces epidermal thickness, reverses disruptions in epidermal architecture, and reduces IL-1 receptor A (IL-1RA) release in 3D keratinocyte skin equivalents generated from primary human keratinocytes and stimulated with mixed lesional T cell supernatants prepared from lichen planus (LP) and cutaneous lupus erythematosus (CLE) patient-derived skin biopsies. Eclitasertib (1 mg/kg) reverses TNF-α- and Z-VAD-induced hypothermia in a mouse model of systemic inflammatory response syndrome.

References

1. Darwish, I., Luo, Z., and Taylor, V. RIP1K inhibitors. *Rigel Pharmaceuticals, Inc.* **WO2021203011A1** (2021).
2. Xia, C., Yao, Z., Xu, L., *et al.* Structure-based bioisosterism design of thio-benzoxazepinones as novel necroptosis inhibitors. *Eur. J. Med. Chem.* **220**, 113484 (2021).
3. Jargosch, M., Wasserer, S., Eigemann, J., *et al.* Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1-mediated chronic inflammatory skin diseases. *J. Allergy Clin. Immunol.* S0091-6749(26)00087-4 (2026).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/20/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM